Shareholders in Grenke (ETR:GLJ) are in the red if they invested five years ago




  • In Business
  • 2022-11-29 05:57:07Z
  • By Simply Wall St.
 

Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Grenke AG (ETR:GLJ) for five years would be nursing their metaphorical wounds since the share price dropped 75% in that time. And we doubt long term believers are the only worried holders, since the stock price has declined 31% over the last twelve months. Furthermore, it's down 12% in about a quarter. That's not much fun for holders.

So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.

View our latest analysis for Grenke

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Looking back five years, both Grenke's share price and EPS declined; the latter at a rate of 1.6% per year. Readers should note that the share price has fallen faster than the EPS, at a rate of 24% per year, over the period. This implies that the market was previously too optimistic about the stock. The low P/E ratio of 9.85 further reflects this reticence.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

We regret to report that Grenke shareholders are down 30% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 14%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 2 warning signs we've spotted with Grenke (including 1 which is concerning) .

We will like Grenke better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DE exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

Is SMA Solar Technology AG (ETR:S92) Potentially Undervalued?
Is SMA Solar Technology AG (ETR:S92) Potentially Undervalued?

While SMA Solar Technology AG ( ETR:S92 ) might not be the most widely known stock at the moment, it led the XTRA...

Is Now The Time To Put TPC Consolidated (ASX:TPC) On Your Watchlist?
Is Now The Time To Put TPC Consolidated (ASX:TPC) On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Recce Pharmaceuticals
Recce Pharmaceuticals' (ASX:RCE) investors will be pleased with their strong 246% return over the last five years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Is Now An Opportune Moment To Examine SEEK Limited (ASX:SEK)?
Is Now An Opportune Moment To Examine SEEK Limited (ASX:SEK)?

SEEK Limited ( ASX:SEK ), might not be a large cap stock, but it led the ASX gainers with a relatively large price hike...

BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders have earned a 54% CAGR over the last three years
BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders have earned a 54% CAGR over the last three years

While BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) shareholders are probably generally happy, the stock hasn't had...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • here
    (2022-11-29 11:37:49Z)

    Advice, insight, and guides to help you create more value through Design Thinking and UX design Join us for actionable advice and practical resources human centered design.Please click and visit us in our website for more details.

    REPLY

Top News: Business